|
|
||||||||
Articles |
Peroxisome proliferator-activated receptors (PPARs) are ligand-activated transcription factors belonging to the nuclear receptor superfamily. PPARalpha is highly expressed in liver, skeletal muscle, kidney, heart and the vascular wall. PPARgamma is predominantly detected in adipose tissue, intestine and macrophages. PPARs are activated by fatty-acid derivatives and pharmacological agents such as fibrates and glitazones which are specific for PPARalpha and PPARgamma respectively. PPARs regulate lipid and lipoprotein metabolism, glucose homeostasis, cell proliferation and differentiation, and apoptosis. PPARalpha controls intra- and extracellular lipid metabolisms whereas PPARgamma triggers adipocyte differentiation and promotes lipid storage. In addition, PPARs also modulate the inflammatory response. PPAR activators have been shown to exert anti-inflammatory activities in various cell types by inhibiting the expression of proinflammatory genes such as cytokines, metalloproteases and acute-phase proteins. PPARs negatively regulate the transcription of inflammatory response genes by antagonizing the AP-1, nuclear factor-kappaB (NF-kappaB), signal transducer and activator of transcription and nuclear factor of activated T-cells signalling pathways and by stimulating the catabolism of proinflammatory eicosanoids. These recent findings indicate a modulatory role for PPARs in inflammation with potential therapeutical applications in chronic inflammatory diseases.
This article has been cited by other articles:
![]() |
D. L. M. van der Meer, T. Degenhardt, S. Vaisanen, P. J. de Groot, M. Heinaniemi, S. C. de Vries, M. Muller, C. Carlberg, and S. Kersten Profiling of promoter occupancy by PPAR{alpha} in human hepatoma cells via ChIP-chip analysis Nucleic Acids Res., January 27, 2010; (2010): gkq012v1 - gkq012. [Abstract] [Full Text] [PDF] |
||||
![]() |
H.-H. Chen, T.-W. Chen, and H. Lin Prostacyclin-induced peroxisome proliferator-activated receptor-{alpha} translocation attenuates NF-{kappa}B and TNF-{alpha} activation after renal ischemia-reperfusion injury Am J Physiol Renal Physiol, October 1, 2009; 297(4): F1109 - F1118. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. M. Alleva, C. Cai, and I. A. Clark Using Complementary and Alternative Medicines to Target the Host Response during Severe Influenza Evid. Based Complement. Altern. Med., September 24, 2009; (2009) nep152v1. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Singh, A. K. Singh, and M. A. Contreras Peroxisomal Dysfunction in Inflammatory Childhood White Matter Disorders: An Unexpected Contributor to Neuropathology J Child Neurol, September 1, 2009; 24(9): 1147 - 1157. [Abstract] [PDF] |
||||
![]() |
W. J. Housley, C. A. O'Conor, F. Nichols, L. Puddington, E. G. Lingenheld, L. Zhu, and R. B. Clark PPAR{gamma} regulates retinoic acid-mediated DC induction of Tregs J. Leukoc. Biol., August 1, 2009; 86(2): 293 - 301. [Abstract] [Full Text] [PDF] |
||||
![]() |
Yulan Liu, Junxia Shi, Jing Lu, Guoquan Meng, Huiling Zhu, Yongqing Hou, Yulong Yin, Shengjun Zhao, and Binying Ding Activation of peroxisome proliferator-activated receptor-{gamma} potentiates pro-inflammatory cytokine production, and adrenal and somatotropic changes of weaned pigs after Escherichia coli lipopolysaccharide challenge Innate Immunity, June 1, 2009; 15(3): 169 - 178. [Abstract] [PDF] |
||||
![]() |
S. J Holdsworth-Carson, M. Permezel, G. E Rice, and M. Lappas Preterm and infection-driven preterm labor: the role of peroxisome proliferator-activated receptors and retinoid X receptor Reproduction, June 1, 2009; 137(6): 1007 - 1015. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. J. Nelson, J. P. Otis, and H. V. Carey A role for nuclear receptors in mammalian hibernation J. Physiol., May 1, 2009; 587(9): 1863 - 1870. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Sobrado, M. P. Pereira, I. Ballesteros, O. Hurtado, D. Fernandez-Lopez, J. M. Pradillo, J. R. Caso, J. Vivancos, F. Nombela, J. Serena, et al. Synthesis of Lipoxin A4 by 5-Lipoxygenase Mediates PPAR{gamma}-Dependent, Neuroprotective Effects of Rosiglitazone in Experimental Stroke J. Neurosci., March 25, 2009; 29(12): 3875 - 3884. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Tawfik, T. Sanders, K. Kahook, S. Akeel, A. Elmarakby, and M. Al-Shabrawey Suppression of Retinal Peroxisome Proliferator-Activated Receptor {gamma} in Experimental Diabetes and Oxygen-Induced Retinopathy: Role of NADPH Oxidase Invest. Ophthalmol. Vis. Sci., February 1, 2009; 50(2): 878 - 884. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Kono, Y. Kamijo, K. Hora, K. Takahashi, M. Higuchi, K. Kiyosawa, H. Shigematsu, F. J. Gonzalez, and T. Aoyama PPAR{alpha} attenuates the proinflammatory response in activated mesangial cells Am J Physiol Renal Physiol, February 1, 2009; 296(2): F328 - F336. [Abstract] [Full Text] [PDF] |
||||
![]() |
O. Yamanaka, K.-i. Miyazaki, A. Kitano, S. Saika, Y. Nakajima, and K. Ikeda Suppression of Injury-Induced Conjunctiva Scarring by Peroxisome Proliferator-Activated Receptor {gamma} Gene Transfer in Mice Invest. Ophthalmol. Vis. Sci., January 1, 2009; 50(1): 187 - 193. [Abstract] [Full Text] [PDF] |
||||
![]() |
J.-C. Fruchart, F. M Sacks, M. P Hermans, G. Assmann, W V. Brown, R. Ceska, M J. Chapman, P. M Dodson, P. Fioretto, H. N Ginsberg, et al. The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patients Diabetes and Vascular Disease Research, November 1, 2008; 5(4): 319 - 335. [Abstract] [PDF] |
||||
![]() |
F. Zapata-Gonzalez, F. Rueda, J. Petriz, P. Domingo, F. Villarroya, J. Diaz-Delfin, M. A. de Madariaga, and J. C. Domingo Human dendritic cell activities are modulated by the omega-3 fatty acid, docosahexaenoic acid, mainly through PPAR{gamma}:RXR heterodimers: comparison with other polyunsaturated fatty acids J. Leukoc. Biol., October 1, 2008; 84(4): 1172 - 1182. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Colin, E. Bourguignon, A.-B. Boullay, J.-J. Tousaint, S. Huet, F. Caira, B. Staels, S. Lestavel, J.-M. A. Lobaccaro, and P. Delerive Intestine-Specific Regulation of PPAR{alpha} Gene Transcription by Liver X Receptors Endocrinology, October 1, 2008; 149(10): 5128 - 5135. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Anderson and J. Borlak Molecular Mechanisms and Therapeutic Targets in Steatosis and Steatohepatitis Pharmacol. Rev., September 1, 2008; 60(3): 311 - 357. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Jaudszus, M. Krokowski, P. Mockel, Y. Darcan, A. Avagyan, P. Matricardi, G. Jahreis, and E. Hamelmann Cis-9,trans-11-Conjugated Linoleic Acid Inhibits Allergic Sensitization and Airway Inflammation via a PPAR{gamma}-Related Mechanism in Mice J. Nutr., July 1, 2008; 138(7): 1336 - 1342. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. B. Rosen, B. D. Abbott, D. C. Wolf, J. C. Corton, C. R. Wood, J. E. Schmid, K. P. Das, R. D. Zehr, E. T. Blair, and C. Lau Gene Profiling in the Livers of Wild-type and PPAR{alpha}-Null Mice Exposed to Perfluorooctanoic Acid Toxicol Pathol, June 1, 2008; 36(4): 592 - 607. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Hoetzel, T. Dolinay, S. Vallbracht, Y. Zhang, H. P. Kim, E. Ifedigbo, S. Alber, A. M. Kaynar, R. Schmidt, S. W. Ryter, et al. Carbon Monoxide Protects against Ventilator-induced Lung Injury via PPAR-{gamma} and Inhibition of Egr-1 Am. J. Respir. Crit. Care Med., June 1, 2008; 177(11): 1223 - 1232. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Ruan, F. Zheng, and Y. Guan PPARs and the kidney in metabolic syndrome Am J Physiol Renal Physiol, May 1, 2008; 294(5): F1032 - F1047. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. H. Remels, H. R. Gosker, P. Schrauwen, R. C. Langen, and A. M. Schols Peroxisome proliferator-activated receptors: a therapeutic target in COPD? Eur. Respir. J., March 1, 2008; 31(3): 502 - 508. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Linard, O. Gremy, and M. Benderitter Reduction of Peroxisome Proliferation-Activated Receptor {gamma} Expression by {gamma}-Irradiation as a Mechanism Contributing to Inflammatory Response in Rat Colon: Modulation by the 5-Aminosalicylic Acid Agonist J. Pharmacol. Exp. Ther., March 1, 2008; 324(3): 911 - 920. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Kamijo, K. Hora, K. Kono, K. Takahashi, M. Higuchi, T. Ehara, K. Kiyosawa, H. Shigematsu, F. J. Gonzalez, and T. Aoyama PPAR{alpha} Protects Proximal Tubular Cells from Acute Fatty Acid Toxicity J. Am. Soc. Nephrol., December 1, 2007; 18(12): 3089 - 3100. [Full Text] [PDF] |
||||
![]() |
M. T. A. Nguyen, S. Favelyukis, A.-K. Nguyen, D. Reichart, P. A. Scott, A. Jenn, R. Liu-Bryan, C. K. Glass, J. G. Neels, and J. M. Olefsky A Subpopulation of Macrophages Infiltrates Hypertrophic Adipose Tissue and Is Activated by Free Fatty Acids via Toll-like Receptors 2 and 4 and JNK-dependent Pathways J. Biol. Chem., November 30, 2007; 282(48): 35279 - 35292. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Szatmari, D. Torocsik, M. Agostini, T. Nagy, M. Gurnell, E. Barta, K. Chatterjee, and L. Nagy PPAR{gamma} regulates the function of human dendritic cells primarily by altering lipid metabolism Blood, November 1, 2007; 110(9): 3271 - 3280. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. M. Lincoff, K. Wolski, S. J. Nicholls, and S. E. Nissen Pioglitazone and Risk of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus: A Meta-analysis of Randomized Trials JAMA, September 12, 2007; 298(10): 1180 - 1188. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. P. Wilding, I. Gause-Nilsson, and A. Persson Tesaglitazar, as add-on therapy to sulphonylurea, dose-dependently improves glucose and lipid abnormalities in patients with type 2 diabetes Diabetes and Vascular Disease Research, September 1, 2007; 4(3): 194 - 203. [Abstract] [PDF] |
||||
![]() |
B. Goke, I. Gause-Nilsson, and A. Persson The effects of tesaglitazar as add-on treatment to metformin in patients with poorly controlled type 2 diabetes Diabetes and Vascular Disease Research, September 1, 2007; 4(3): 204 - 213. [Abstract] [PDF] |
||||
![]() |
G. D'Agostino, G. La Rana, R. Russo, O. Sasso, A. Iacono, E. Esposito, G. M. Raso, S. Cuzzocrea, J. Lo Verme, D. Piomelli, et al. Acute Intracerebroventricular Administration of Palmitoylethanolamide, an Endogenous Peroxisome Proliferator-Activated Receptor-{alpha} Agonist, Modulates Carrageenan-Induced Paw Edema in Mice J. Pharmacol. Exp. Ther., September 1, 2007; 322(3): 1137 - 1143. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. K. LeBrasseur, T.-A. S. Duhaney, D. S. De Silva, L. Cui, P. C. Ip, L. Joseph, and F. Sam Effects of Fenofibrate on Cardiac Remodeling in Aldosterone-Induced Hypertension Hypertension, September 1, 2007; 50(3): 489 - 496. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. M. Hall and D. P. McDonnell The Molecular Mechanisms Underlying the Proinflammatory Actions of Thiazolidinediones in Human Macrophages Mol. Endocrinol., August 1, 2007; 21(8): 1756 - 1768. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. M. Perez-Ortiz, P. Tranque, M. Burgos, C. F. Vaquero, and J. Llopis Glitazones Induce Astroglioma Cell Death by Releasing Reactive Oxygen Species from Mitochondria: Modulation of Cytotoxicity by Nitric Oxide Mol. Pharmacol., August 1, 2007; 72(2): 407 - 417. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. E.J. Teunissen, P. J.H. Smeets, P. H.M. Willemsen, L. J. De Windt, G. J. Van der Vusse, and M. Van Bilsen Activation of PPAR{delta} inhibits cardiac fibroblast proliferation and the transdifferentiation into myofibroblasts Cardiovasc Res, August 1, 2007; 75(3): 519 - 529. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Saika, O. Yamanaka, Y. Okada, T. Miyamoto, A. Kitano, K. C. Flanders, Y. Ohnishi, Y. Nakajima, W. W.-Y. Kao, and K. Ikeda Effect of overexpression of ppar{gamma} on the healing process of corneal alkali burn in mice Am J Physiol Cell Physiol, July 1, 2007; 293(1): C75 - C86. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Zapata-Gonzalez, F. Rueda, J. Petriz, P. Domingo, F. Villarroya, A. de Madariaga, and J. C. Domingo 9-cis-Retinoic Acid (9cRA), a Retinoid X Receptor (RXR) Ligand, Exerts Immunosuppressive Effects on Dendritic Cells by RXR-Dependent Activation: Inhibition of Peroxisome Proliferator-Activated Receptor {gamma} Blocks Some of the 9cRA Activities, and Precludes Them to Mature Phenotype Development J. Immunol., May 15, 2007; 178(10): 6130 - 6139. [Abstract] [Full Text] [PDF] |
||||
![]() |
T.-A. S. Duhaney, L. Cui, M. K. Rude, N. K. Lebrasseur, S. Ngoy, D. S. De Silva, D. A. Siwik, R. Liao, and F. Sam Peroxisome Proliferator-Activated Receptor {alpha}-Independent Actions of Fenofibrate Exacerbates Left Ventricular Dilation and Fibrosis in Chronic Pressure Overload Hypertension, May 1, 2007; 49(5): 1084 - 1094. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. A. Wohlfert, F. C. Nichols, E. Nevius, and R. B. Clark Peroxisome Proliferator-Activated Receptor {gamma} (PPAR{gamma}) and Immunoregulation: Enhancement of Regulatory T Cells through PPAR{gamma}-Dependent and -Independent Mechanisms J. Immunol., April 1, 2007; 178(7): 4129 - 4135. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. T. Chambers, S. M. Weber, and J. A. Corbett PGJ2-stimulated beta-cell apoptosis is associated with prolonged UPR activation Am J Physiol Endocrinol Metab, April 1, 2007; 292(4): E1052 - E1061. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Chintalgattu, G. S. Harris, S. M. Akula, and L. C. Katwa PPAR-{gamma} agonists induce the expression of VEGF and its receptors in cultured cardiac myofibroblasts Cardiovasc Res, April 1, 2007; 74(1): 140 - 150. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. A. Spector and A. W. Norris Action of epoxyeicosatrienoic acids on cellular function Am J Physiol Cell Physiol, March 1, 2007; 292(3): C996 - C1012. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. N. Finck The PPAR regulatory system in cardiac physiology and disease Cardiovasc Res, January 15, 2007; 73(2): 269 - 277. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Kamijo, K. Hora, T. Nakajima, K. Kono, K. Takahashi, Y. Ito, M. Higuchi, K. Kiyosawa, H. Shigematsu, F. J. Gonzalez, et al. Peroxisome Proliferator-Activated Receptor {alpha} Protects against Glomerulonephritis Induced by Long-Term Exposure to the Plasticizer Di-(2-Ethylhexyl)Phthalate J. Am. Soc. Nephrol., January 1, 2007; 18(1): 176 - 188. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. R. Sirtori HDL and the progression of atherosclerosis: new insights Eur. Heart J. Suppl., October 1, 2006; 8(suppl_F): F4 - F9. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Venteclef, J. C. Smith, B. Goodwin, and P. Delerive Liver Receptor Homolog 1 Is a Negative Regulator of the Hepatic Acute-Phase Response Mol. Cell. Biol., September 15, 2006; 26(18): 6799 - 6807. [Abstract] [Full Text] [PDF] |
||||
![]() |
G Rogler Significance of anti-inflammatory effects of PPAR{gamma} agonists? Gut, August 1, 2006; 55(8): 1067 - 1069. [Full Text] [PDF] |
||||
![]() |
I A Leclercq, C Sempoux, P Starkel, and Y Horsmans Limited therapeutic efficacy of pioglitazone on progression of hepatic fibrosis in rats Gut, July 1, 2006; 55(7): 1020 - 1029. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. M. Tovar and D. B. Schering Management of Dyslipidemia in Special Populations Journal of Pharmacy Practice, April 1, 2006; 19(2): 63 - 78. [Abstract] [PDF] |
||||
![]() |
N. Sato, F. A. Moore, B. C. Kone, L. Zou, M. A. Smith, M. A. Childs, S. Moore-Olufemi, S. G. Schultz, and R. A. Kozar Differential induction of PPAR-{gamma} by luminal glutamine and iNOS by luminal arginine in the rodent postischemic small bowel Am J Physiol Gastrointest Liver Physiol, April 1, 2006; 290(4): G616 - G623. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Paumelle, C. Blanquart, O. Briand, O. Barbier, C. Duhem, G. Woerly, F. Percevault, J.-C. Fruchart, D. Dombrowicz, C. Glineur, et al. Acute Antiinflammatory Properties of Statins Involve Peroxisome Proliferator-Activated Receptor-{alpha} via Inhibition of the Protein Kinase C Signaling Pathway Circ. Res., February 17, 2006; 98(3): 361 - 369. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Blaschke, Y. Takata, E. Caglayan, R. E. Law, and W. A. Hsueh Obesity, Peroxisome Proliferator-Activated Receptor, and Atherosclerosis in Type 2 Diabetes Arterioscler Thromb Vasc Biol, January 1, 2006; 26(1): 28 - 40. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. E Minge, N. K. Ryan, K. H. V. D. Hoek, R. L. Robker, and R. J. Norman Troglitazone Regulates Peroxisome Proliferator-Activated Receptors and Inducible Nitric Oxide Synthase in Murine Ovarian Macrophages Biol Reprod, January 1, 2006; 74(1): 153 - 160. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. F. Cariello, E. H. Romach, H. M. Colton, H. Ni, L. Yoon, J. G. Falls, W. Casey, D. Creech, S. P. Anderson, G. R. Benavides, et al. Gene Expression Profiling of the PPAR-alpha Agonist Ciprofibrate in the Cynomolgus Monkey Liver Toxicol. Sci., November 1, 2005; 88(1): 250 - 264. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. E. Ackerman IV, X. L. Zhang, B. H. Rovin, and D. A. Kniss Modulation of Cytokine-Induced Cyclooxygenase 2 Expression by PPARG Ligands Through NF{kappa}B Signal Disruption in Human WISH and Amnion Cells Biol Reprod, September 1, 2005; 73(3): 527 - 535. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Leibovici, H. B. Grossman, C. P. Dinney, R. E. Millikan, S. Lerner, Y. Wang, J. Gu, Q. Dong, and X. Wu Polymorphisms in Inflammation Genes and Bladder Cancer: From Initiation to Recurrence, Progression, and Survival J. Clin. Oncol., August 20, 2005; 23(24): 5746 - 5756. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Li, N. Gokden, M. D. Okusa, R. Bhatt, and D. Portilla Anti-inflammatory effect of fibrate protects from cisplatin-induced ARF Am J Physiol Renal Physiol, August 1, 2005; 289(2): F469 - F480. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. A. Burgess, L. E. Daugherty, T. H. Thatcher, H. F. Lakatos, D. M. Ray, M. Redonnet, R. P. Phipps, and P. J. Sime PPAR{gamma} agonists inhibit TGF-{beta} induced pulmonary myofibroblast differentiation and collagen production: implications for therapy of lung fibrosis Am J Physiol Lung Cell Mol Physiol, June 1, 2005; 288(6): L1146 - L1153. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Mouthiers, A. Baillet, C. Delomenie, D. Porquet, and N. Mejdoubi-Charef Peroxisome Proliferator-Activated Receptor {alpha} Physically Interacts with CCAAT/Enhancer Binding Protein (C/EBP{beta}) to Inhibit C/EBP{beta}-Responsive {alpha}1-Acid Glycoprotein Gene Expression Mol. Endocrinol., May 1, 2005; 19(5): 1135 - 1146. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Migita and J. Morser 15-Deoxy-{Delta}12,14-Prostaglandin J2 (15d-PGJ2) Signals Through Retinoic Acid Receptor-Related Orphan Receptor-{alpha} but Not Peroxisome Proliferator-Activated Receptor-{gamma} in Human Vascular Endothelial Cells: The Effect of 15d-PGJ2 on Tumor Necrosis Factor-{alpha}-Induced Gene Expression Arterioscler Thromb Vasc Biol, April 1, 2005; 25(4): 710 - 716. [Abstract] [Full Text] [PDF] |
||||
![]() |
NINDS ICH Workshop Participants Priorities for Clinical Research in Intracerebral Hemorrhage: Report From a National Institute of Neurological Disorders and Stroke Workshop Stroke, March 1, 2005; 36(3): e23 - e41. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. L. Schiffrin Peroxisome proliferator-activated receptors and cardiovascular remodeling Am J Physiol Heart Circ Physiol, March 1, 2005; 288(3): H1037 - H1043. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Xu, M. Gen, L. Lu, J. Fox, S. O. Weiss, R. D. Brown, D. Perlov, H. Ahmad, P. Zhu, C. Greyson, et al. PPAR-{gamma} activation fails to provide myocardial protection in ischemia and reperfusion in pigs Am J Physiol Heart Circ Physiol, March 1, 2005; 288(3): H1314 - H1323. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Genovese, S. Cuzzocrea, R. Di Paola, E. Mazzon, C. Mastruzzo, P. Catalano, M. Sortino, N. Crimi, A. P. Caputi, C. Thiemermann, et al. Effect of rosiglitazone and 15-deoxy-{Delta}12,14-prostaglandin J2 on bleomycin-induced lung injury Eur. Respir. J., February 1, 2005; 25(2): 225 - 234. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Guan Peroxisome Proliferator-Activated Receptor Family and Its Relationship to Renal Complications of the Metabolic Syndrome J. Am. Soc. Nephrol., November 1, 2004; 15(11): 2801 - 2815. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Harant and I. J. D. Lindley Negative cross-talk between the human orphan nuclear receptor Nur77/NAK-1/TR3 and nuclear factor-{kappa}B Nucleic Acids Res., October 5, 2004; 32(17): 5280 - 5290. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. L. DeCicco, T. Tanaka, F. Andreola, and L. M. De Luca The effect of thalidomide on non-small cell lung cancer (NSCLC) cell lines: possible involvement in the PPAR{gamma} pathway Carcinogenesis, October 1, 2004; 25(10): 1805 - 1812. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Kleemann, L. Verschuren, B.-J. de Rooij, J. Lindeman, M. M. de Maat, A. J. Szalai, H. M. G. Princen, and T. Kooistra Evidence for anti-inflammatory activity of statins and PPAR{alpha} activators in human C-reactive protein transgenic mice in vivo and in cultured human hepatocytes in vitro Blood, June 1, 2004; 103(11): 4188 - 4194. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Srinivasan, M. E. Hatley, K. B. Reilly, E. C. Danziger, and C. C. Hedrick Modulation of PPAR{alpha} Expression and Inflammatory Interleukin-6 Production by Chronic Glucose Increases Monocyte/Endothelial Adhesion Arterioscler Thromb Vasc Biol, May 1, 2004; 24(5): 851 - 857. [Abstract] [Full Text] |
||||
![]() |
P. Gervois, R. Kleemann, A. Pilon, F. Percevault, W. Koenig, B. Staels, and T. Kooistra Global Suppression of IL-6-induced Acute Phase Response Gene Expression after Chronic in Vivo Treatment with the Peroxisome Proliferator-activated Receptor-{alpha} Activator Fenofibrate J. Biol. Chem., April 16, 2004; 279(16): 16154 - 16160. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. M. Weber, A. L. Scarim, and J. A. Corbett PPAR{gamma} is not required for the inhibitory actions of PGJ2 on cytokine signaling in pancreatic {beta}-cells Am J Physiol Endocrinol Metab, March 1, 2004; 286(3): E329 - E336. [Abstract] [Full Text] |
||||
![]() |
M. Meissner, M. Stein, C. Urbich, K. Reisinger, G. Suske, B. Staels, R. Kaufmann, and J. Gille PPAR{alpha} Activators Inhibit Vascular Endothelial Growth Factor Receptor-2 Expression by Repressing Sp1-Dependent DNA Binding and Transactivation Circ. Res., February 20, 2004; 94(3): 324 - 332. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. N. Muller, J. Theuer, E. Shagdarsuren, E. Kaergel, H. Honeck, J.-K. Park, M. Markovic, E. Barbosa-Sicard, R. Dechend, M. Wellner, et al. A Peroxisome Proliferator-Activated Receptor-{alpha} Activator Induces Renal CYP2C23 Activity and Protects from Angiotensin II-Induced Renal Injury Am. J. Pathol., February 1, 2004; 164(2): 521 - 532. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. A. Hsueh and D. Bruemmer Peroxisome Proliferator-Activated Receptor {gamma}: Implications for Cardiovascular Disease Hypertension, February 1, 2004; 43(2): 297 - 305. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Sartipy and D. J. Loskutoff Expression Profiling Identifies Genes That Continue to Respond to Insulin in Adipocytes Made Insulin-resistant by Treatment with Tumor Necrosis Factor-{alpha} J. Biol. Chem., December 26, 2003; 278(52): 52298 - 52306. [Abstract] [Full Text] [PDF] |
||||
![]() |
T.-l. Yue, W. Bao, B. M. Jucker, J.-l. Gu, A. M. Romanic, P. J. Brown, J. Cui, D. T. Thudium, R. Boyce, C. L. Burns-Kurtis, et al. Activation of Peroxisome Proliferator-Activated Receptor-{alpha} Protects the Heart From Ischemia/Reperfusion Injury Circulation, November 11, 2003; 108(19): 2393 - 2399. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. L. Schiffrin, F. Amiri, K. Benkirane, M. Iglarz, and Q. N. Diep Peroxisome Proliferator-Activated Receptors: Vascular and Cardiac Effects in Hypertension Hypertension, October 1, 2003; 42(4): 664 - 668. [Abstract] [Full Text] [PDF] |
||||
![]() |
O. Barbier, D. Duran-Sandoval, I. Pineda-Torra, V. Kosykh, J.-C. Fruchart, and B. Staels Peroxisome Proliferator-activated Receptor {alpha} Induces Hepatic Expression of the Human Bile Acid Glucuronidating UDP-glucuronosyltransferase 2B4 Enzyme J. Biol. Chem., August 29, 2003; 278(35): 32852 - 32860. [Abstract] [Full Text] [PDF] |
||||
![]() |
Q. Yan, J. Zhang, H. Liu, S. Babu-Khan, R. Vassar, A. L. Biere, M. Citron, and G. Landreth Anti-Inflammatory Drug Therapy Alters {beta}-Amyloid Processing and Deposition in an Animal Model of Alzheimer's Disease J. Neurosci., August 20, 2003; 23(20): 7504 - 7509. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Woerly, K. Honda, M. Loyens, J.-P. Papin, J. Auwerx, B. Staels, M. Capron, and D. Dombrowicz Peroxisome Proliferator-activated Receptors {alpha} and {gamma} Down-regulate Allergic Inflammation and Eosinophil Activation J. Exp. Med., August 4, 2003; 198(3): 411 - 421. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Schachter Review: Lipid lowering drugs, inflammation and cardiovascular disease The British Journal of Diabetes & Vascular Disease, May 1, 2003; 3(3): 178 - 182. [Abstract] [PDF] |
||||
![]() |
O. Barbier, L. Villeneuve, V. Bocher, C. Fontaine, I. P. Torra, C. Duhem, V. Kosykh, J.-C. Fruchart, C. Guillemette, and B. Staels The UDP-glucuronosyltransferase 1A9 Enzyme Is a Peroxisome Proliferator-activated Receptor alpha and gamma Target Gene J. Biol. Chem., April 11, 2003; 278(16): 13975 - 13983. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Kleemann, P. P. Gervois, L. Verschuren, B. Staels, H. M. G. Princen, and T. Kooistra Fibrates down-regulate IL-1-stimulated C-reactive protein gene expression in hepatocytes by reducing nuclear p50-NFkappa B-C/EBP-beta complex formation Blood, January 15, 2003; 101(2): 545 - 551. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Duez, Y.-S. Chao, M. Hernandez, G. Torpier, P. Poulain, S. Mundt, Z. Mallat, E. Teissier, C. A. Burton, A. Tedgui, et al. Reduction of Atherosclerosis by the Peroxisome Proliferator-activated Receptor alpha Agonist Fenofibrate in Mice J. Biol. Chem., December 6, 2002; 277(50): 48051 - 48057. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. D. Girnun, F. E. Domann, S. A. Moore, and M. E. C. Robbins Identification of a Functional Peroxisome Proliferator-Activated Receptor Response Element in the Rat Catalase Promoter Mol. Endocrinol., December 1, 2002; 16(12): 2793 - 2801. [Abstract] [Full Text] [PDF] |
||||
![]() |
U. Kintscher, C. Lyon, S. Wakino, D. Bruemmer, X. Feng, S. Goetze, K. Graf, A. Moustakas, B. Staels, E. Fleck, et al. PPAR{alpha} Inhibits TGF-{beta}-Induced {beta}5 Integrin Transcription in Vascular Smooth Muscle Cells by Interacting With Smad4 Circ. Res., November 29, 2002; 91 (11): e35 - e44. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. E. Clay, A. Monjazeb, J. Thorburn, F. H. Chilton, and K. P. High 15-Deoxy-{Delta}12,14-prostaglandin J2-induced apoptosis does not require PPAR{gamma} in breast cancer cells J. Lipid Res., November 1, 2002; 43(11): 1818 - 1828. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Kluft, R. Kleemann, and M.P.M. de Maat How best to counteract the enemies? By controlling inflammation in the coronary circulation Eur. Heart J. Suppl., November 1, 2002; 4(suppl_G): G53 - G65. [Abstract] [PDF] |
||||
![]() |
N. Wang, L. Verna, N.-G. Chen, J. Chen, H. Li, B. M. Forman, and M. B. Stemerman Constitutive Activation of Peroxisome Proliferator-activated Receptor-gamma Suppresses Pro-inflammatory Adhesion Molecules in Human Vascular Endothelial Cells J. Biol. Chem., September 6, 2002; 277(37): 34176 - 34181. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Eberhardt, E.-S. Akool, J. Rebhan, S. Frank, K.-F. Beck, R. Franzen, F. M. A. Hamada, and J. Pfeilschifter Inhibition of Cytokine-induced Matrix Metalloproteinase 9 Expression by Peroxisome Proliferator-activated Receptor alpha Agonists Is Indirect and Due to a NO-mediated Reduction of mRNA Stability J. Biol. Chem., August 30, 2002; 277(36): 33518 - 33528. [Abstract] [Full Text] [PDF] |
||||
![]() |
O. Barbier, I. P. Torra, Y. Duguay, C. Blanquart, J.-C. Fruchart, C. Glineur, and B. Staels Pleiotropic Actions of Peroxisome Proliferator-Activated Receptors in Lipid Metabolism and Atherosclerosis Arterioscler Thromb Vasc Biol, May 1, 2002; 22(5): 717 - 726. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. M. Flavell, Y. Jamshidi, E. Hawe, I. Pineda Torra, M.-R. Taskinen, M. H. Frick, M. S. Nieminen, Y. A. Kesaniemi, A. Pasternack, B. Staels, et al. Peroxisome Proliferator-Activated Receptor {alpha} Gene Variants Influence Progression of Coronary Atherosclerosis and Risk of Coronary Artery Disease Circulation, March 26, 2002; 105(12): 1440 - 1445. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | CONTACT US | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |